| 查看: 173 | 回复: 0 | |||
| 当前主题已经存档。 | |||
abcd888898银虫 (正式写手)
|
[交流]
【转帖】Novo Nordisk starts phase 1 trial with long-acting oral GLP-1 analogue
|
||
|
Emisphere earns 2 million US dollar milestone payment(13 Jan 2010) Novo Nordisk today announced that it has initiated its first phase 1 clinical trial with a long-acting oral GLP-1 analogue (NN9924). This milestone releases a 2 million dollar payment to Emisphere Technologies, Inc., whose proprietary Eligen® Technology is used in the formulation of NN9924. GLP-1 (Glucagon-Like Peptide-1) is a natural hormone involved in controlling blood sugar levels. It stimulates the release of insulin only when blood sugar levels become too high. In people with type 2 diabetes, GLP-1 secretion is often impaired. The aim of the trial, which is conducted in the UK, is to investigate the safety, tolerability and bioavailability of NN9924 in healthy volunteers. Results from the trial, which is planned to enrol about 155 people, are expected to be reported in 2011. There are many challenges in developing a formulation of GLP-1 for oral use, in particular obtaining adequate bioavailability (absorption of the drug in the body). NN9924 addresses some of the key challenges, and utilises the Eligen® formulation technology from Emisphere to facilitate GLP-1 absorption from the gut. |
回复此楼» 猜你喜欢
求助冯连芳、张才亮的《聚合过程强化技术》
已经有1人回复
-
2026考博
已经有0人回复
-
药物学论文润色/翻译怎么收费?
已经有130人回复
-
浙江中医药大学张勇民院士2026年博士研究生招生
已经有3人回复
-
硫醚氧化
已经有2人回复
-
26博士申请-药物化学方向
已经有32人回复
-
求助cortellis数据库查询针对靶点ABCC6的药物和在研分子
已经有1人回复
-
章慧等编著的《配位化学：原理与应用》
已经有1人回复
-
求助！！！大佬救命！！！
已经有4人回复
-
酰胺缩合
已经有3人回复